Centering discussion on a patient case of metastatic breast cancer, expert oncologist Hope Rugo, MD, FASCO, highlights systemic therapy selection and best practices in this setting.
EP. 1: Case Overview: A 57-Year-Old Woman with HR+/HER2- Metastatic Breast Cancer
Expert oncologist Hope Rugo, MD, FASCO, reviews the diagnosis and treatment of a 57-year-old woman with HR+/HER2- metastatic breast cancer (mBC).
EP. 2: The Role of ESR1 Mutations and Approaches to Biomarker Testing in Endocrine-Resistant Breast Cancer
Expert perspective on the role of ESR1 mutations in HR+/HER2- mBC and best practices on biomarker testing for patients experiencing disease progression on endocrine therapy.
EP. 3: Treatment Options for HR+/HER2- Metastatic Breast Cancer with Disease Progression on Standard-of-Care Therapy
A comprehensive review of treatment options for patients with HR+/HER2- metastatic breast cancer who experience disease progression on standard-of-care therapies such as combination CDK4/6 and aromatase inhibitors.
EP. 4: Elacestrant Therapy in HR+/HER2- Metastatic Breast Cancer: The EMERALD Trial
Centering discussion on the EMERALD trial, Dr Hope Rugo, reflects on the safety and efficacy of elacestrant in patients with HR+/HER2- mBC.
EP. 5: Selecting Optimal Second- and Third-Line Therapy for HR+/HER2- mBC
Dr Hope Rugo shares insight on how she approaches second-line and higher treatment selection in patients with HR+/HER2- metastatic breast cancer who experience disease progression on first-line therapy.
EP. 6: HR+/HER2 Metastatic Breast Cancer: Future Directions in Care
Closing out her discussion on the treatment and management of HR+/HER2- mBC, Hope Rugo, MD, FASCO, highlights unmet needs and future directions in the field.
2 Commerce Drive Cranbury, NJ 08512